Jefferies Remains a Buy on WuXi XDC Cayman, Inc. (2268)

TipRanksJan 22 07:18 ET · Ratings

【Brokerage Focus】Jianyin International maintains the outperform rating on WUXI XDC (02268) and expects it to achieve positive free cash flow by the end of this fiscal year.

Jinwu Financial News | Jianyin International released a Research Report indicating that WUXI XDC (02268) has announced a positive earnings forecast for 2024, with total revenue/Net income/adjusted earnings (non-International Financial Reporting Standards) all growing year-on-year by over 85%/260%/170%, surpassing the bank's previous expectations of 52%/176%/112%. The company attributes this growth to: (1) the downstream demand for antibody-drug conjugates (ADC), particularly in the USA Biotechnology sector; (2) increased utilization of existing production facilities. The bank noted that the number of integrated projects recently signed by the company has increased from 202

Jinwu Financial NewsJan 21 22:31 ET

[Brokerage Focus] Industrial Securities maintains WUXI XDC (02268) 'Shareholding' rating, expects the company's long-term growth rate to exceed the growth rate of the ADC Industry.

Jinwu Financial News | According to a research report from Industrial Securities, WUXI XDC (02268) is expected to achieve year-on-year revenue, net profit, and adjusted net profit growth of over 85%, 260%, and 170% respectively in 2024. The performance growth is mainly due to: 1. The continuous strong development of the downstream ADC and other bioconjugate drug industries; 2. The company has a leading position and competitive advantage as a global leader in ADC outsourcing; 3. Production facilities maintain high capacity utilization, and new capacities are being added successively, with stable operational efficiency growth, leading to continuous improvement in the company's profit margins. The report indicates that the company's Wuxi base covers the four core production lines for ADCs.

Jingwu Financial NewsJan 21 02:15 ET

Express News | Morgan Stanley's Long Position in WuXi XDC Cayman Decreases to 1.97% on Jan 15 From 5.63% - HKEX

ReutersJan 20 04:09 ET

Hong Kong stock movement | WUXI XDC (02268) gained over 5% as the ADC Industry rapidly expands its demand. The company's revenue growth in 2024 is significantly higher than the guidance provided at the beginning of the year.

WUXI XDC (02268) rose over 5%, as of the time of writing, it increased by 5.21% to 30.3 Hong Kong dollars, with a trading volume of 59.955 million Hong Kong dollars.

Zhitong FinanceJan 19 20:59 ET

Morgan Stanley maintains WUXI XDC's Shareholding rating with a Target Price of 34.8 Hong Kong dollars.

Morgan Stanley released a research report stating that it maintains the "Shareholding" rating for WUXI XDC (02268) with a Target Price of 34.8 Hong Kong dollars. The company has announced strong performance for 2024 in advance and has also provided guidance for at least 35% performance growth by 2025, expressing confidence in achieving a compound annual growth rate of about 31% from 2024 to 2030, which is above the Industry average. The bank noted that WUXI XDC will launch the DP3 factory in mid-2025 and begin production in Singapore by the end of 2025, preparing for Global commercial projects. Morgan Stanley believes that the positive guidance for 2025 and robust long-term goals further highlight the group's rapid growth.

新浪港股Jan 17 01:26 ET